在核的VGF Accumbens调节突触和阿片类诱发的可塑性
bioRxiv : the preprint server for biology
|December 19, 2025
概括
神经前体VGF调节了核的塑性和阿片类药物敏感性. VGF中断放大了阿片类药物引起的精神运动敏感性,这表明VGF是阿片类药物使用障碍的治疗目标.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经显著影响核 (NAc) 功能,并奖励神经电路.
- 了解NAc中的神经机制可能会揭示新的成治疗点.
- 神经前体VGF在药物引起的可塑性中的作用在很大程度上尚未被探索.
研究的目的:
- 调查VGF在NAc中的作用.
- 确定VGF对突触可塑性和阿片类药物引起的反应的贡献.
- 评估VGF对与阿片类药物敏感性相关的行为的影响.
主要方法:
- 在NAc内部神经元和中等脊状神经元中表达VGF的特征.
- 研究了VGF衍生的TLQP-62对激发性突触传播的影响.
- 在NAc中利用VGF的条件遗传淘汰来评估阿片类药物敏感性和精神运动敏感性.
主要成果:
- 在NAc内部神经元和中等脊状神经元中表达VGF.
- 来自VGF的TLQP-62降低了激发性突触传输到NAc中等棘手神经元.
- 在长期暴露于芬太尼后,NAc放大了阿片类药物引起的精神运动敏感度,而没有改变急性阿片类药物敏感度.
结论:
- 在NAc中,VGF作为突触和阿片类药物引起的可塑性调节器.
- 在阿片类药物暴露后,VGF在NAc可塑性中的作用为阿片类药物使用障碍的潜在治疗标.
- 对VGF的机制进行进一步的研究可能有助于更好地理解药物引起的适应.
相关概念视频
Opioid Receptors: Overview
3.9K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
3.9K
Neurochemical Transmission: Sites of Drug Action
3.4K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
790
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790
Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.7K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.7K
Excitatory and Inhibitory Effects of Neurotransmitters
12.5K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
12.5K
GPCR Desensitization
7.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.9K


